Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Racura OncologyASX:RAC -4.05%25 Cash Ratio is 18.12 as of Dec. 2025, which is 49% above its 10-year median of 12.20. GuruFocus rates ASX:RAC with a GF Score™ of 25/100. Among 1,385 Biotechnology companies, Racura Oncology ranks better than 91.62% on this metric.
Racura Oncology has a Cash Ratio of 18.12. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Racura Oncology's Cash Ratio or its related term are showing as below:
ASX:RAC'
s Cash Ratio Range Over the Past 10 Years
Min: 4.66 Med: 12.2 Max: 48.92
Current: 18.12
During the past 10 years, Racura Oncology's highest Cash Ratio was 48.92. The lowest was 4.66. And the median was 12.20.
ASX:RAC's Cash Ratio is ranked better than 91.62% of 1385
companies
in the Biotechnology industry
Industry Median: 2.95
vs ASX:RAC: 18.12
Racura Oncology (ASX:RAC) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Racura Oncology Cash Ratio Related Terms
Racura Oncology Cash Ratio Historical Data
* Premium members only.
The historical data trend for Racura Oncology's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:RAC vs VRTX, REGN, ALNY: Cash Ratio Comparison
For the Biotechnology subindustry, Racura Oncology's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Racura Oncology Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Racura Oncology's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Racura Oncology's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Racura Oncology (ASX:RAC) has a Cash Ratio of 18.12 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Racura Oncology and its competitors. This is 49% above median its historical median of 12.20. Over the past decade, Racura Oncology's Cash Ratio has ranged from 4.66 to 48.92. According to the industry distribution chart, Racura Oncology ranks #116 out of 1385 companies in the Biotechnology industry, placing it in the top 8.4%.
Is Racura Oncology's Cash Ratio too high?
Racura Oncology's current Cash Ratio of 18.12 is 49% above median its 10-year median of 12.20. Over the past 10 years, this metric has ranged from a low of 4.66 to a high of 48.92. The Biotechnology industry median Cash Ratio is 2.95. Racura Oncology's value of 18.12 is 514.2% above this industry median. Based on the distribution chart, Racura Oncology ranks #116 out of 1385 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Racura Oncology has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Racura Oncology's Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Racura Oncology ranks #116 out of 1385 companies for Cash Ratio. This places Racura Oncology in the top 8% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 2.95. Racura Oncology's value of 18.12 is 514.2% above this benchmark. Historically, Racura Oncology's own Cash Ratio has ranged from 4.66 to 48.92 over the past decade. While the company's 10-year median is 12.20 vs. the industry median of 2.95, Racura Oncology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.95, based on 1,385 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Racura Oncology's current Cash Ratio of 18.12 is 514.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Racura Oncology and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Racura Oncology's current Cash Ratio is 18.12, which is 49% above median its own 10-year median of 12.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Racura Oncology stock overvalued right now?
Racura Oncology (ASX:RAC) has a current Cash Ratio of 18.12. The current Cash Ratio is 18.12, which is 49% above median its 10-year median of 12.20 and 514.2% above the Biotechnology industry median of 2.95. Racura Oncology's overall GF Score™ is 25/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Racura Oncology (ASX:RAC), the current Cash Ratio is 18.12 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Racura Oncology Ltd is a developer of an oncology therapeutics platform designed to develop targeted cancer treatments. The company offers precision oncology drug development, biomarker-driven research, and cancer metabolism therapies, enabling healthcare providers and cancer patients to access targeted treatment options with improved therapeutic outcomes.
25GF Score
Get the complete analysis for ASX:RAC
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:RAC has been successfully added to your 
